Vaccine News and Research

Latest Vaccine News and Research

Study suggests honey and Nigella sativa expedites viral clearance in COVID-19 patients

A team of researchers from various institutes across Pakistan, Chile, Canada, and the USA recently conducted a clinical trial to investigate the potential effectiveness of a combination of honey and Nigella sativa (HNS) in treating COVID-19 patients. Their study is published on the preprint server medRxiv prior to the scientific peer review process.

8 Nov 2020

Innate immunity key to limiting viral load in COVID-19 cases

As the coronavirus disease 2019 (COVID-19) pandemic continues to cause many difficulties for public health authorities, research is ongoing to understand how the virus can cause fatal effects on those infected and thereby suggest effective preventive and therapeutic measures against it.

8 Nov 2020

Universal nanoparticle platform may help in rapid development of a COVID-19 vaccine

A research group in China recently published a paper on the pre-print server bioRxiv* that reports the performance of a potentially universal nanoparticle platform that may prove useful for the rapid development of a COVID-19 vaccine, as well as other vaccines in the future.

8 Nov 2020

Survey: Only few children with rheumatic diseases report contracting COVID-19

Results from a large, international survey shows that only a small fraction of children with rheumatic diseases reported contracting COVID-19.

6 Nov 2020

People of color with rheumatic disease have worse COVID-19 outcomes

New research at ACR Convergence, the American College of Rheumatology's annual meeting, reveals that people of color with rheumatic disease have worse health outcomes from COVID-19 infection, are more likely to be hospitalized to treat their coronavirus infection, and are more likely to require invasive ventilator treatment

6 Nov 2020

Study: Genetically edited form of herpes simplex virus outperforms leading vaccine candidate

A genetically edited form of a herpes simplex virus -- rewired to keep it from taking refuge in the nervous system and eluding an immune response -- has outperformed a leading vaccine candidate in a new study from the University of Cincinnati, Northwestern University and the University of Nebraska-Lincoln.

6 Nov 2020

VA joins Pentagon in recruiting volunteers for COVID vaccine trials

The Department of Veterans Affairs is recruiting 8,000 volunteers for the Phase 3 clinical trials of at least four COVID-19 vaccine candidates at 20 federal medical facilities across the U.S., according to officials with the VA and Operation Warp Speed, the Trump administration's initiative to fast-track a coronavirus vaccine.

6 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

UNICEF and WHO issue urgent call to action to avert measles, polio epidemics

UNICEF and the World Health Organization (WHO) today issued an urgent call to action to avert major measles and polio epidemics as COVID-19 continues to disrupt immunization services worldwide, leaving millions of vulnerable children at heightened risk of preventable childhood diseases.

6 Nov 2020

Persistent and extensive lung damage seen in COVID-19 patients

A team of researchers at the University of Trieste in Italy aimed to determine the extent and the causes of lung damage from COVID-19 to better understand the pathological correlates of the disease.

5 Nov 2020

Llama antibodies could be a potent nanoweapon against COVID-19

Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.

5 Nov 2020

Children produce different antibodies in response to infection with new coronavirus

Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.

5 Nov 2020

Argonne supports the largest analysis of COVID-19 genome sequences in the U.S.

Argonne computational resources supported the largest comprehensive analysis of COVID-19 genome sequences in the U.S. and helped corroborate growing evidence of a protein mutation.

5 Nov 2020

Study shows T cells can prevent Zika infection in mice

Where Aedes mosquitoes fly, Zika virus may not be far behind. Although the explosive 2015–2016 Zika epidemics in the Americas are behind us, Zika may re-emerge, and "in many countries, Zika may be spreading in silence," says Sujan Shresta, Ph.D., a professor at La Jolla Institute for Immunology (LJI).

5 Nov 2020

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.

4 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Will an effective COVID-19 vaccine return life to normal in the US?

A new study has shown that the extent to which social distancing restrictions and face mask usage could be relaxed in the United States during the coronavirus disease 2019 (COVID-19) pandemic would greatly depend on how effective a vaccine is and the proportion of the population it covered.

4 Nov 2020

HPV vaccines found to be safe and well-tolerated in males

Human papillomavirus (HPV) is one of the most common sexually transmitted infections and cases various cancers in women and men.

4 Nov 2020

Discoverey of four SARS-CoV-2 Mpro inhibitors, boceprevir, calpain inhibitors II and XII and GC-376

A team of scientists from the United States has recently revealed that small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease exhibit potent antiviral activity. These inhibitors show better efficacy when used in combination with antiviral medicine Remdesivir. The study is currently available on the bioRxiv* preprint server.

3 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020